119 related articles for article (PubMed ID: 28823393)
1. Cutaneous Metastases From Adenocarcinoma of the Prostate.
Flores-Terry MÁ; Cruz-Conde de Boom R; García-Arpa M; de Lara-Simón IM
Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):360. PubMed ID: 28823393
[No Abstract] [Full Text] [Related]
2. Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer.
Sofie Lichtwarck Bjugn F; Storjord E; Kristensen RM; Brekke OL
Scand J Urol; 2019; 53(2-3):171-173. PubMed ID: 30714461
[No Abstract] [Full Text] [Related]
3. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
Ferlicot S
Ann Pathol; 2017 Jun; 37(3):235-240. PubMed ID: 28522123
[No Abstract] [Full Text] [Related]
4. Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient.
Lobato-Berezo A; March-Rodríguez A; Deza G; Bertolín-Colilla M; Pujol RM
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e291-e292. PubMed ID: 29377270
[No Abstract] [Full Text] [Related]
5. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
6. [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Nagashima T; Niiro M; Hirayama K; Date S; Okihara K; Mukaisho K
Hinyokika Kiyo; 2012 Aug; 58(8):457-60. PubMed ID: 23052274
[TBL] [Abstract][Full Text] [Related]
7. Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy.
Doreswamy K; Karthikeyan VS; Nagabhushana M; Shankaranand B
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26153290
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer - androgen deprivation: intermittent or continuous?].
Wedel SA
Aktuelle Urol; 2014 May; 45(3):180-1. PubMed ID: 24932555
[No Abstract] [Full Text] [Related]
9. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093-4. PubMed ID: 24209518
[No Abstract] [Full Text] [Related]
10. Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Sciarra A
Eur Urol; 2013 Dec; 64(6):1014-5. PubMed ID: 24209449
[No Abstract] [Full Text] [Related]
11. Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more.
Fui MN; Grossmann M
Asian J Androl; 2013 Jul; 15(4):445-6. PubMed ID: 23685907
[No Abstract] [Full Text] [Related]
12. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Lee KC; Bradley DA; Hussain M; Meyer CR; Chenevert TL; Jacobson JA; Johnson TD; Galban CJ; Rehemtulla A; Pienta KJ; Ross BD
Neoplasia; 2007 Dec; 9(12):1003-11. PubMed ID: 18084607
[TBL] [Abstract][Full Text] [Related]
13. [Brainstem metastasis from a prostate adenocarcinoma in the context of Muir-Torre syndrome].
Aldave G; Pay E; Queipo F; Idoate MA; Guridi J
Neurocirugia (Astur); 2013; 24(2):78-81. PubMed ID: 23177734
[TBL] [Abstract][Full Text] [Related]
14. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Njiaju UO; Truica CI
Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
[TBL] [Abstract][Full Text] [Related]
15. Lack of energy, petechiae, elevated PSA level--Dx?
Subramaniam S; Choufani E; Manov A
J Fam Pract; 2014 Oct; 63(10):565-7. PubMed ID: 25343154
[No Abstract] [Full Text] [Related]
16. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
17. Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
Pinto F; Brescia A; Sacco E; Volpe A; Gardi M; Gulino G; Bassi P
Arch Ital Urol Androl; 2009 Dec; 81(4):212-4. PubMed ID: 20608143
[TBL] [Abstract][Full Text] [Related]
18. Urological cancer: walking the tightrope of survival and quality of life with ADT.
Resnick MJ
Nat Rev Clin Oncol; 2013 Jun; 10(6):307-8. PubMed ID: 23648827
[No Abstract] [Full Text] [Related]
19. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
20. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
